Products OLAPARIB
OLAPARIB Phase 2 Completed ⚡ Active Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Dec 22, 2016 → Dec 3, 2020
About OLAPARIB OLAPARIB is a phase 2 stage product being developed by AstraZeneca for Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity. The current trial status is completed. This product is registered under clinical trial identifier NCT02983799. Target conditions include Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT03063710 Pre-clinical Completed — — PSR Ovarian Cancer With a BRCA Mutation NCT05501548 Phase 2 Terminated Jun 30, 2023 Oct 14, 2024 Prostate Cancer NCT04951492 Phase 2 Terminated Nov 9, 2022 Oct 15, 2023 Castration-Resistant Prostate Carcinoma NCT05482074 Phase 2 Withdrawn Oct 4, 2022 May 1, 2027 Recurrent Metastatic Melanoma NCT05262608 Phase 2 UNKNOWN Dec 7, 2021 Apr 26, 2024 Prostate Cancer NCT04884360 Phase 3 Active May 31, 2021 Jul 27, 2027 Ovarian Cancer NCT04515836 Phase 2 Recruiting Feb 19, 2021 Apr 15, 2028 Mesothelioma NCT04532645 Pre-clinical Completed Jan 7, 2021 Sep 27, 2024 Ovary Cancer NCT04421963 Phase 3 Active Aug 4, 2020 Apr 6, 2027 Ovarian Cancer NCT04330040 Approved Completed May 25, 2020 Sep 30, 2022 Ovarian Cancer NCT04236414 Phase 1 Completed Jan 14, 2020 Feb 4, 2025 Solid Tumours NCT03782818 Phase 1/2 Terminated Nov 20, 2019 Oct 31, 2024 Pulmonary Arterial Hypertension NCT03829345 Phase 2 UNKNOWN Jul 2, 2019 Feb 14, 2022 Oesophageal Cancer NCT03786796 Phase 2 Recruiting Jun 3, 2019 Mar 1, 2028 Renal Cell Carcinoma NCT03955640 Phase 1 Terminated May 20, 2019 Aug 26, 2021 Metastatic Malignant Neoplasm in the Chest Wall NCT03742895 Phase 2 Active Dec 12, 2018 Jun 30, 2026 Advanced Solid Neoplasms NCT04152941 Pre-clinical Completed Oct 11, 2018 Feb 11, 2020 Relapsed Ovarian Cancers Patients NCT03570476 Phase 2 Terminated Sep 11, 2018 Jul 3, 2019 Prostate Adenocarcinoma Without Neuroendocrine Differentiation NCT03470805 Phase 2 Completed Jun 21, 2018 Jul 27, 2022 Ovarian Cancer NCT03448718 Phase 2 Completed Apr 17, 2018 Oct 15, 2021 Metastatic Urothelial Cancer
Competing Products 20 competing products in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3
Other Products from AstraZeneca